THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [6.12]-C43 ID: TIP-MED-000313

Desmopressin Acetate

Active Ingredient / Scientific Identity: Desmopressin Acetate • Class: Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Desmopressin Acetate ([6.12]-C43 | ID: TIP-MED-000313) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/6-12-c43-desmopressin-acetate/
Generic / Entity NameDesmopressin Acetate ([6.12]-C43)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassErgot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule
Available Dosage FormsCabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Mel
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirr
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Desmopressin Acetate (TIP-MED-000313, Reference Code [6.12]-C43) is classified under Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [6.12] (Cabergoline & Desmopressin Acetate). Representative Indian Market Examples (Edition 2.7 Ch 06 [6.12], p. 77): Cabergoline: Cabgolin (Sun), Dostinex (Pfizer), Camforte. Desmopressin: Minirin / Minirin Melt (Ferring), Dpressin — Strengths & Dosage Forms: Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray
Co-indexed constituent under primary monograph [6.12] (Cabergoline & Desmopressin Acetate). Representative Indian Market Examples (Edition 2.7 Ch 06 [6.12], p. 77): Cabergoline: Cabgolin (Sun), Dostinex (Pfizer), Camforte. Desmopressin: Minirin / Minirin Melt (Ferring), Dpressin — Strengths & Dosage Forms: Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray
Dosage Forms & Available Strengths:
Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H) acting on target receptor/enzyme pathways in Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06): clinical efficacy is mediated via Ergot-Derived Dopamine D2 Receptor Agonist & Synthetic Vasopressin (V2) Analogue (Schedule H) for Cabergoline: Hyperprolactinaemia, prolactinoma (pituitary micro/macroadenoma), and inhibition/suppression of physiological lactation. Desmopressin: Central Diabetes Insipidus (CDI), nocturnal polyuria, and primary nocturnal enuresis.

4. Therapeutic Indications & Evidence-Supported Uses

  • Cabergoline: Hyperprolactinaemia, prolactinoma (pituitary micro/macroadenoma), and inhibition/suppression of physiological lactation
  • Desmopressin: Central Diabetes Insipidus (CDI), nocturnal polyuria, and primary nocturnal enuresis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Cabergoline: Hyperprolactinaemia: Start 0.25 mg PO TWICE weekly (e.g., Monday & Thursday), titrate monthly to 0.5–1 mg twice weekly; Lactation Inhibition: 1 mg (two 0.5 mg tabs) single dose on Day 1 postpartum. Desmopressin: CDI: 0.1–0.2 mg PO BD–TDS; Enuresis: 0.2 mg PO (or 120 mcg Melt) at bedtime

Administration & Meal Timing: Take Cabergoline WITH dinner or at bedtime with food. For Desmopressin in nocturnal enuresis/polyuria: RESTRICT fluid intake from 1 hour BEFORE until 8 hours AFTER the bedtime dose! | Cabergoline: Twice Weekly (e.g., Mon & Thu evening) with food. Desmopressin: Bedtime (Enuresis) or BD–TDS (CDI)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [6.12].
Metabolism & Biotransformation:
Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis
Elimination & Renal Adjustment:
Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis
Hepatic Impairment Considerations:
Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Cabergoline CONTRAINDICATED in pre-eclampsia/postpartum hypertension, cardiac valvulopathy, and pulmonary/pericardial/retroperitoneal fibrosis. Desmopressin CONTRAINDICATED in habitual/psychogenic polydipsia, baseline Serum Na+ <135 mEq/L, moderate-to-severe CKD (CrCl <50 mL/min), SIADH, and heart failure!

Key Clinical Precautions: Renal: Desmopressin is renally cleared — CONTRAINDICATED if CrCl <50 mL/min! Hepatic: Reduce Cabergoline in Child–Pugh C cirrhosis

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Cabergoline: Nausea, postural dizziness, headache, constipation. Desmopressin: Headache, hyponatraemia, nausea
  • Cabergoline: Postural syncope, fibrotic cardiac valvulopathy, impulse-control disorders. Desmopressin: SEVERE WATER INTOXICATION & HYPONATRAEMIC SEIZURES/COMA (Na+ <125 mEq/L) if fluids are not restricted!
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Cabergoline: D2 antagonists (Domperidone, Metoclopramide, Levosulpiride, Risperidone, Haloperidol) directly oppose Cabergoline and raise prolactin! Macrolides increase Cabergoline levels
    • Desmopressin: SSRIs, Carbamazepine, Oxcarbazepine, Thiazides, and NSAIDs markedly increase hyponatraemia risk!

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [6.12].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: For Cabgolin: take ONLY twice a week (not daily!) with dinner; for Minirin: stop drinking fluids 1 hour before bedtime until next morning to prevent dangerous brain swelling/low sodium, and hold Minirin during acute vomiting/diarrhoea or fever
    • Meal & Clock Timing Instruction: Take Cabergoline WITH dinner or at bedtime with food. For Desmopressin in nocturnal enuresis/polyuria: RESTRICT fluid intake from 1 hour BEFORE until 8 hours AFTER the bedtime dose! (Cabergoline: Twice Weekly (e.g., Mon & Thu evening) with food. Desmopressin: Bedtime (Enuresis) or BD–TDS (CDI))
    • Missed Dose Protocol: Cabergoline: Take within 1–2 days if missed. Desmopressin: Never double dose
    • Geriatric Dispensing Pearl: AVOID Desmopressin for nocturia in older adults >=65 years (AGS Beers 2023 & STOPP v3: very high incidence of severe life-threatening hyponatraemia!)

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Cabergoline Tablets: 0.25 mg, 0.5 mg. Desmopressin Tablets: 0.1 mg (100 mcg), 0.2 mg (200 mcg); Sublingual Melt: 60 mcg, 120 mcg; Nasal Spray: 10 mcg/spray

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/6-12-c43-desmopressin-acetate/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.